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Abstract
Many of melatonin’s actions are mediated through interaction with the G-protein coupled
membrane bound melatonin receptors type 1 and type 2 (MT1 and MT2, respectively) or,
indirectly with nuclear orphan receptors from the RORα/RZR family. Melatonin also binds to the
quinone reductase II enzyme, previously defined the MT3 receptor. Melatonin receptors are
widely distributed in the body; herein we summarize their expression and actions in non-neural
tissues. Several controversies still exist regarding, for example, whether melatonin binds the
RORα/RZR family. Studies of the peripheral distribution of melatonin receptors are important
since they are attractive targets for immunomodulation, regulation of endocrine, reproductive and
cardiovascular functions, modulation of skin pigmentation, hair growth, cancerogenesis, and
aging. Melatonin receptor agonists and antagonists have an exciting future since they could define
multiple mechanisms by which melatonin modulates the complexity of such a wide variety of
physiological and pathological processes.
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1. Introduction to melatonin, its biosynthesis and metabolism
Melatonin (N-acetyl-5-methoxytrypamine) has been known for over 50 years when Lerner et
al. characterized and isolated this indolamine from the bovine pineal gland and found that it
caused the lightening of the frog skin (Lerner et al., 1959), thus, identifying the
depigmenting factor first described in 1917 by McCord and Allen (Lerner, 1960).
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Accordingly, Lerner along with his co-workers were the first to define chemical structure of
this compound as N-acetyl-5-methoxytrypamine and to show that it acts as an antagonist of
the α-melanocyte stimulating hormone (α-MSH) (Lerner et al., 1960).
It took some time thereafter to establish the biosynthetic pathway of melatonin. The
synthesis of melatonin is a multistep process, which starts with hydroxylation of aromatic
amino acid L-tryptophan to 5-hydroxytryptophan catalyzed by tryptophan hydroxylase
(TPH, EC 1.14.16.4), which uses 6-tetrahydropterin (6-BH4) as an essential co-factor for
this reaction (McIsaac and Page, 1959; Schallreuter et al., 1994). 5-Hydroxytryptophan is
then converted to serotonin (5-hydroxytryptamine) by the aromatic amino acid
decarboxylase (AAD, EC 4.1.1.28) (Lovenberg et al., 1962). Serotonin is subsequently
converted to N-acetylserotonin by the enzyme arylalkylamine N-acetyltransferase (AANAT,
EC 2.3.1.87) (Lovenberg et al., 1967). The final step of melatonin synthesis is the
conversion of N-acetylserotonin to melatonin by hydroxyindole-O-methyl transferase
(HIOMT, EC 2.1.1.4) (Weissbach, 1960). The correct designation of HIOMT is serotonin N-
acetyltransferase (ASMT) and is described in great detail by Stehle et al. (2011). The
biosynthetic pathway of melatonin is shown in Fig. 1.
Both the AANAT and HIOMT have been considered the rate limiting steps in melatonin
production, however Liu and Borjigin have found that HIOMT is not the rate-limiting
enzyme in melatonin synthesis (Brydon et al., 1999; Liu and Borjigin, 2005; Reiter, 1991c).
Also, it has been documented that serotonin can also be acetylated to N-acetylserotonin by
an alternative enzyme, most likely arylamine N-acetyltransferase (NAT1) (Liu and Borjigin,
2005; Slominski et al., 2005a, 2003).
There are three major pathways of melatonin degradation: (1) the classical hepatic
degradation pathway that generates 6-hydroxymelatonin (Facciola et al., 2001; Reiter,
1991c), (2) the alternative indolic pathway that produces 5-methoxyindole acetic acid (5-
MIAA) or 5-methoxytryptophol (5-MTOL) (Grace et al., 1991; Rogawski et al., 1979), and
(3) the kynuric pathway that produces N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK)
(Hardeland et al., 1993; Hirata et al., 1974; Slominski et al., 2008; Tan et al., 2007). In the
classical melatonin degradation pathway, the liver CYP P450 enzymes CYP1A1, CYP1A2,
and CYP1B1 metabolize melatonin to 6-hydroxymelatonin (Ma et al., 2005). This product is
then conjugated with either sulfate or glucuronide and then secreted in the urine (Arendt,
1988). In the liver, melatonin can also be demethylated to N-acetylserotonin by either
CYP2C19 or CYP1A (Facciola et al., 2001).
The alternative indolic pathway involves melatonin being metabolized to 5-
methoxytryptamine by melatonin deacetylase (Grace et al., 1991; Rogawski et al., 1979;
Slominski et al., 2005a). 5-Methoxytryptamine is then converted by monoamine oxidase to
5-methoxyindoleacetaldehyde, which is further enzymatically metabolized to either 5-MIAA
or 5-MTOL by aldehyde dehydrogenase and alcohol dehydrogenase, respectively (Grace et
al., 1991; Rogawski et al., 1979; Slominski et al., 2005a). Recent studies performed on liver
have indicated, however, that both mitochondrial and microsomal cytochrome P450s
metabolize melatonin predominantly by 6-hydroxylation, with O-demethylation representing
a minor metabolic pathway (Semak et al., 2008).
In the kynuric pathway, cleavage of the pyrrole ring of melatonin by indoleamine 2,3-
dioxygenase yields AFMK, which is further metabolized by arylamine formamidase to form
N1-acetyl-5-methoxykynuramine (AMK) (Hardeland et al., 1993; Hirata et al., 1974). The
kynurenic acid degradation pathway can also be executed by other enzymes, including
peroxidase, and myeloperoxidase (reviewed in Slominski et al. (2008)). The free radical
species have also been shown to be involved in a non-enzymatic kynurenic pathway (Tan et
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al., 2000, 2007). Additional route of melatonin degradation in mitochondria to AFMK by
cytochrome C was also described (Semak et al., 2005).
Melatonin is widely distributed in plants, unicellular organisms, algae, bacteria,
invertebrates, and vertebrates (Hardeland and Poeggeler, 2003; Iriti et al., 2010; Stehle et al.,
2011). Its uncommonly wide distribution allows it to carry out its pleiotropic functions
(Celinski et al., 2011; Gomez-Moreno et al., 2010; Jung-Hynes et al., 2010; Paradies et al.,
2010; Reiter, 1991a; Reiter et al., 2010; Slominski et al., 2008; Tan et al., 2007). In
vertebrates, the roles of melatonin are numerous and include: regulating circadian rhythm
and acting as a neuromodulator, hormone, cytokine and biological response modifier (Man
et al., 2011; Reiter, 1991b). It also affects brain, immune, gastrointestinal, cardiovascular,
renal, bone and endocrine functions, and acts as an oncostatic and anti-aging molecule
(Celinski et al., 2011; Leja-Szpak et al., 2010; Pandi-Perumal et al., 2008; Slominski et al.,
2008; Yu et al., 1993). Many of melatonin’s actions are mediated through the interaction
with specific membranereceptors. Examples include anticonvulsant and vasoconstrictor
activity through activation of MT1 receptors, and vasodilation via activation of MT2
receptors (Masana et al., 2002). Melatonin has also been found to have a protective effect
against myocardial infarction, to limit weight gain, and to inhibit the effects of estrogen
(Boutin et al., 2005; Tan et al., 2011, 1998; Tengattini et al., 2008).
Melatonin also acts through non-receptor mediated mechanisms, for example serving as a
scavenger for reactive oxygen species and reactive nitrogen species (Gomez-Moreno et al.,
2010). The reactive species melatonin scavenges include hydroxyl radical (HO−), hydrogen
peroxide (H2O2), nitric oxide (NO−), and various others (Galano et al., 2011; Tan et al.,
2001, 1993). Melatonin reacts with agents to form products that are not recycled back to
melatonin, making it a “suicidal antioxidant” (Tan et al., 2001). Melatonin, in addition to
being a broad-spectrum antioxidant, can also activate cytoprotective enzymes (Rodriguez et
al., 2004). At both physiological and pharmacological concentrations melatonin attenuates
or counteracts oxidative stress, and regulates cellular metabolism (Korkmaz et al., 2009;
Slominski et al., 2005a, 2008; Tan et al., 2007). Some of these protective effects of
melatonin are shared by its metabolite, AFMK (Tan et al., 2007).
Melatonin is synthesized in the pineal gland (Reiter, 1991c). After entering circulation
melatonin acts as endocrine factor and a chemical messenger of light and darkness
(circadian and circannual pacemaker) (Reiter, 1993). Evidence has accumulated that it is
also produced in the various extra-pineal organs including the brain, retina, retinal pigment
epithelium, gastrointestinal tract, bone marrow, lymphocytes, and the skin (Bubenik, 2002;
Pandi-Perumal et al., 2008; Slominski et al., 2008; Tan et al., 2003). In these organs
melatonin may signal in autocrine or paracrine modes, including the possibility that it acts
via intracellular receptors expressed by the same cells that produces the molecules
(Slominski et al., 2008; Tan et al., 2003). Also, locally produced melatonin could protect the
cell from free radical-mediated damage.
2. Melatonin receptors
As of 2011, there have been two membrane bound melatonin receptors identified and
characterized, MT1 and MT2. MT1 was known as Mel1a, and MT2 as Mel1b (Dubocovich
et al., 2010, 1998). Both of them belong to the family of G protein-coupled, seven
transmembrane receptors (Dubocovich et al., 2003; Witt-Enderby et al., 2003). Activation of
either Gi or Gq, depending on the receptor type, mediates intracellular signaling by
modifying the activities of adenylate cyclase, phospholipases C and A2, potassium and
calcium channels, and guanylyl cyclase (Pandi-Perumal et al., 2008). The existence of a
third membrane bound melatonin binding site (MT3 receptor) was theorized at one time
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(Dubocovich, 1995). However, this biological target of melatonin was found to actually be
the cytosolic enzyme, quinone reductase 2 (Nosjean et al., 2000; Vincent et al., 2010).
Below, we discuss the signaling mechanism by each of these receptors and describe the
primary pharmacological tools used to define them.
2.1. MT1 receptor
The MT1 receptor (Mel1c) was first cloned in frogs nearly 20 years ago (Ebisawa et al.,
1994). The same group was the first to clone the mammalian MT1 receptor from sheep and
humans (Reppert et al., 1994). The MT1 receptor is 350 amino acids in length and coupled
to Gi, specifically Giα2, Giα3, and Gq/11. MT1 receptors are expressed in the brain,
cardiovascular system (including peripheral blood vessels, aorta and heart), immune system,
testes, ovary, skin, liver, kidney, adrenal cortex, placenta, breast, retina, pancreas and spleen
(Dubocovich and Markowska, 2005; Fischer et al., 2008b; Pandi-Perumal et al., 2008;
Slominski et al., 2005a, 2008). In the brain, the receptor is predominantly found in the
hypothalamus, cerebellum, hippocampus, substantia nigra and ventral tegmental area
(Pandi-Perumal et al., 2008). Subsequent investigation, however, may well identify even a
larger range of the MT1 receptor.
2.2. MT2 receptor
The MT2 receptor was cloned by Reppert and his co-workers (Reppert et al., 1995) from
brain, retina and human pituitary gland. The gene contains two exons and one intron and the
final translated protein product consists of 363 amino acids and shows 60% homology to the
MT1 receptor (Reppert et al., 1996a). The MT2 receptor is also a G-protein related and
couples to the activation of Gi. MT2 has been found in the immune system, brain
(hypothalamus, Suprachiasmatic Nucleus (SCN)), retina, pituitary, blood vessels, testes,
kidney, gastrointestinal tract, mammary glands, adipose tissue, and the skin (Dubocovich et
al., 2005; Reppert et al., 1995; Roca et al., 1996; Slominski et al., 2005a).
An orphan receptor called the melatonin related receptor (MRR) or GPR50 has 45% amino
acid homology to melatonin receptors (Dufourny et al., 2008). Despite this homology,
melatonin does not bind to GPR50 and the identity of its real ligand is unclear (Reppert et
al., 1996b). However, GPR50 may heterodimerize with the MT1 receptor and inhibit its
activity (Levoye et al., 2006a,b).
2.3. Quinone reductase II (NQO2; “MT3” receptor)
Although the “MT3” receptor has not yet been found in humans, it is expressed in the
hamster (Nosjean et al., 2001). The highest levels were found in the liver and the kidneys
with moderate amounts in the heart, adipose tissue, and the brain (Nosjean et al., 2001). It is
also expressed in the retina of the rabbit (Pintor et al., 2001). The properties of the “MT3”
receptor include: it has a low affinity or 2-[125I]iodomelatonin, unlike MT1 and MT2
(Reppert et al., 1996b); it is not coupled to G proteins; it has a nanomolar affinity for
melatonin and is not sensitive to Na+, Mg+2, Ca+2 (Dubocovich, 1995). Nosjean and his co-
workers reported that “MT3” is equivalent to NQO2 (Nosjean et al., 2000). The three
modulators for the “MT3” receptor, ranked from the lowest to highest affinity, are
melatonin, resveratrol, and compound S29434 (Ferry et al., 2010).
2.4. Nuclear receptors
There are over 200 genes activated by nuclear receptors (Jetten, 2009); of these, melatonin
may mediate its actions through the ROR/RZR (retinoid orphan receptors/retinoid Z
receptors) group (Smirnov, 2001). The subfamilies that, according to some authors, bind
melatonin include: RZRα, RORα, RORα2, and RZRβ (Becker-Andre et al., 1994; Carrillo-
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Vico et al., 2005). The structure of the nuclear receptors consist of an N-terminal domain, a
DNA binding domain that contains a zinc double finger, a hinge region, and a ligand-
binding domain included in the C-terminal (Jetten, 2009; Smirnov, 2001). The nuclear
receptor groups are distributed according to their subtype, with RZRβ being found in
neuronal tissues and RZRα in adipose tissue, the skin, testes, cartilage, and liver (Smirnov,
2001).
The question of whether melatonin interacts directly with these nuclear receptors has been a
source of controversy. Becker-Andre and his co-workers had theorized that melatonin
interacts with the nuclear receptors of the retinoic acid subfamily of orphan receptors
(Becker-Andre et al., 1994; Carlberg et al., 1994). Thus, they summarized that melatonin
acts as a ligand to the previously identified orphan receptor RZRβ. These workers
discovered this by cloning a cDNA of the RZRβ. They then transfected drosophila SL-3
cells and HELA cells and measured binding of 2-[125I]Iodomelatonin to the nuclear receptor
(Becker-Andre et al., 1994). Concurrently, Carlberg and his co-workers found that
melatonin might interact with nuclear receptors of the retinoic acid subfamily of orphan
receptors (RORα/RZR) (Carlberg et al., 1994). A year later, Wiesenberg and co-workers
used a similar technique, and confirmed that melatonin can also bind to RZRα and RORα1
(Wiesenberg et al., 1995). However, some investigators question the ability of melatonin to
bind to the nuclear receptor RORα and to directly activate it (Dai et al., 2001). Importantly,
the crystal structure of RORα was obtained by Kallen and his co-workers and cholesterol
sulfate was defined as the natural ligand for it (Kallen et al., 2004). Other compounds were
also listed as potential ligands for RORα nuclear receptor including cholesterol derivatives,
however, melatonin was not cited among them (Bitsch et al., 2003).
Some investigators propose that melatonin indirectly regulates nuclear receptors via the
MT1 membrane receptor that are known to be activated by melatonin (Dai et al., 2001; Ram
et al., 2002). Ram and his co-workers tested this idea by measuring a RORα-luciferase
reporter activity assay. They found that melatonin and N-acetyl-4-aminomethyl-6-
methoxy-9-methyl-1,2,3,4-tetrahydrocarbazole (AMMTC) suppresses RORα transcriptional
activity, while CBPT (MT1 antagonist) reverses the effects of melatonin and AMMTC (Ram
et al., 2002). Nevertheless investigators in the field of nuclear receptors question the
hypothesis that melatonin is a native ligand for ROR (Jetten, 2009).
2.5. Signaling by MT1 and MT2 receptors
Morgan and his co-workers reported that the membrane bound melatonin receptors are
coupled to the G protein, Gi, in ovine pars tuberalis (Morgan et al., 1989). However, Abe
and his co-workers were the first to show that melatonin inhibits the action of melanocyte
stimulating hormone (MSH) and prevents the formation of cAMP (Abe et al., 1969). Both
MT1 and MT2 receptors are found to be a part of the G protein-coupled receptor
superfamily (Jockers et al., 2008). The G protein coupled receptors include 7α helical
transmembrane domains and activate G protein signaling pathways (Hall et al., 1999).
Navajas and his collegues claimed that melatonin interacts with a binding pocket formed by
helices V, VI, and VII of the receptor (Navajas et al., 1996). The MT1 receptor is coupled to
the G protein subunits Gi2, Gi3, and Gq/11 (Brydon et al., 1999).The Gi coupled MT1
receptor lowers cAMP levels (Capsoni et al., 1994). Gi exerts this action through the
inhibition of adenylyl cyclase activity directly via Gi, but also via signaling by the βγ
subunit, which inhibits certain adenylyl cyclase isoforms and activates PLCβ and PLCε
(Hildebrandt, 1997; Witt-Enderby et al., 2003). The MT1 receptor can also be coupled via
Gi to the Kir3 potassium channel (Nelson et al., 1996).
In some cells, MT1 receptors couple to Gq/11 and the activation of phospholipase-C, which
in turn can increase calcium levels and activate signaling by calmodulin (CaM), CaM
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kinases and calreticulin (Witt-Enderby et al., 2003). Membrane melatonin receptors also
promote the activity of c-Jun-N-terminal kinase (JNK), but the precise signaling pathway for
this action has not been clearly delineated (Chan et al., 2002). A schematic diagram of
melatonin receptor signaling is shown in Fig. 2.
Interestingly, both MT1 and MT2 can form homo and heterodimers (Ayoub et al., 2002).
Dimerization has been demonstrated via bioluminescence resonance energy transfer (BRET)
(Ayoub et al., 2002). The same group observed that the MT1 homodimers occur at almost
the same rate as the MT1–MT2 heterodimers, while the MT2 homodimers occur about 3–4
times less abundantly than the heterodimers (Ayoub et al., 2004). It is unclear what, if any,
pharmacological properties or physiological effects of melatonin are dependent upon
formation of these different receptor dimeric species.
3. Melatonin receptors in the cardiovascular system
3.1. Vasculature
Viswanathan et al. discovered melatonin receptors in vascular tissue though the use of 2-
[125I]iodomelatonin binding (Viswanathan et al., 1990). According to their calculations, the
dissociation constant in the anterior cerebral artery was 3.4 × 10−11 M, while it was 1.05 ×
10−10 M in the caudal artery (Viswanathan et al., 1990). Melatonin has been found to be a
vasorelaxant in the mesenteric artery and aorta (Girouard et al., 2001). In contrast, in the
caudal artery, melatonin has also been found to be a vasoconstrictor (Krause et al., 1995;
Ting et al., 1997). Interestingly, in a study performed by Doolen and co-workers, the
vascular response of the caudal artery was shown to be dependent on the concentration of
melatonin (Doolen et al., 1998). At concentrations of 10−10–10−7 M, it was found to be a
vasoconstrictor; however, at concentrations 10−7–10−5 M, melatonin was found to reduce
vasoconstriction (Doolen et al., 1998). After the addition of the MT2 antagonist 4P-ADOT,
vasoconstriction with higher concentrations of melatonin was restored, showing that MT2
receptors could mediate vasoconstriction (Doolen et al., 1998). Masana and co-workers
further explored the role of MT1 versus MT2 receptors in vascular activity. They
documented that MT1 mediates vascular constriction, while MT2 mediates vasodilation
(Masana et al., 2002).
3.2. Melatonin as an antihypertensive molecule
One potential pharmacological use of melatonin is in lowering hypertension.
When 23-week old rats were treated with 6 mg melatonin daily for 5 days, they had a mean
blood pressure 180 mm Hg versus the 195 mm Hg for the vehicle treated ones (Kawashima
et al., 1987). Pinealectomy had previously been reported to have a slight hypertensive
response: thus, blood pressure of pinealectomized rats was found to be 20 mm Hg higher on
average than sham operated rats (Holmes and Sugden, 1976; Zanoboni and Zanoboni-
Muciaccia, 1967). In an attempt to resolve this discrepancy, Lusardi and his colleagues
performed a double blind study where human subjects were given 5 mg of melatonin per day
for 4 weeks (Lusardi et al., 1997). In this study, melatonin was found to reduce the blood
pressure in humans by about 6 mm Hg (Lusardi et al., 1997). Unexpectedly, when patients
taking nifedepine (a calcium channel blocker and antihypertensive) were also given
melatonin, the indoleamine actually caused the blood pressure of the nifedipine users to
increase by 6 mm Hg (Lusardi et al., 2000). The authors speculated that the melatonin might
interact with calcium–calmodulin signaling (Lusardi et al., 2000). A number of authors have
found that melatonin has been found to reduce the systolic blood pressure in humans
(Gomez-Moreno et al., 2010; Paulis et al., 2010).
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4. Melatonin receptors in the immune system
The first study that demonstrated a connection between the immune system and the pineal
gland was performed almost four decades ago, where pinealectomy caused a depression in
the immune system (Csaba and Barath, 1975). These investigators also showed that the
thymic cells had stopped proliferating following surgical removal of the pineal gland. Even
earlier studies had been published the results of which hinted at melatonin’s role in the
immune system. In 1926, Bergman and co-workers gave the cats pineal gland extracts, and
this resulted in the cats having a stronger immune system in so far as it could be measured
(Carrillo-Vico et al., 2005). Another earlier study has shown that pinealectomy causes the
thymus gland to shrink from 130 to 70 mg in mice (Vaughan and Reiter, 1971). A likely
correlation between pinealectomy and immune system depression was also confirmed by
Beskonakli and co-workers, where removal of the pineal gland resulted in a reduction in the
number of lymphocytes, erythrocytes, and leukocytes (Beskonakli et al., 2001).
The first study that showed a direct relationship between the immune system and melatonin
was published by Maestroni and co-workers in 1986 (Maestroni et al., 1986). These
investigators reported that the immune system function was inhibited by propanolol and p-
chlorophenylalanine; however, when melatonin was administered, the immune system was
restored to essentially normal levels (Maestroni et al., 1986). The potential role of opioid
receptor antagonists (naltrexone and ICI 174864) in the regulation of melatonin’s
immunostimulatory effect. The results demonstrated that naltrexone decreases the amount of
splenocyte activity by half, while ICI 174864 had no effect on melatonin’s action (Maestroni
et al., 1988). Thus melatonin modulates immune cell activity via μ- and k-opioid, but not ∂-
opioid receptors. For additional information on the complex actions of melatonin on immune
functions, the reader should consult following reviews (Carrillo-Vico et al., 2005; Kim et al.,
2009).
4.1. Melatonin receptor expression in immune cells
The first major study to identify membrane melatonin receptors in the immune system was
published by Lopez-Gonzalez and co-workers; in their report, they uncovered melatonin
recepotors in lymphocytes (Lopez-Gonzalez et al., 1992). The MT1 receptor expressed in
the thymus and the spleen, as well as in CD4, CD8, and B cells, while MT2 receptors were
not detected in any of these cells (Pozo et al., 1997). The MT1 receptor is also expressed in
U937 cells (Guerrero et al., 2000). Carillo-Vico and co-workers reported the presence of the
MT2 receptor in the thymus, as well as confirming that the MT1 receptor is expressed in the
thymus, spleen, and lymphocytes (Carrillo-Vico et al., 2003). In addition, MT2 receptor
inhibits leukocyte rolling, while “MT3” receptor reportedly regulate the adhesion of
leukocytes to the vascular endothelium (Lotufo et al., 2001).
4.2. Nuclear receptors in the immune system
Melatonin nuclear receptors reportedly influence the immune system physiology; these
receptors were first proposed to be in the immune system by Menendez-Pelaez et al. (1993).
Steinhilber and co-workers performed the first investigation that directly established a
correlation between the nuclear melatonin receptors and the immune system, where the
action of melatonin was in inhibiting 5-lipoxygenase syntheses in B lymphocytes
(Steinhilber et al., 1995). The importance of nuclear receptors was also verified by Garcia-
Maurino’s group Garcia-Maurino et al., 1997, who found that IL-2, IL-6, and INF-γ
synthesis in the CD4 cells was mediated at the level of the nucleus. They also found that
nuclear receptors mediate the production of IL-2 and IL-6 production in both lymphocytic
(Jurkat) cells and human peripheral mononuclear cells (Garcia-Maurino et al., 2000).
Melatonin was found to activate the cells to produce both IL-2 and IL-6. That IL-2
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production is mediated by a nuclear melatonin receptor in U937 cells was claimed by
Guerrero et al. (2000). However, these investigators used IFN-γ, which not only inhibits the
MT1 receptor but also stimulates nuclear receptors.
A number of studies have examined to define the distribution of nuclear melatonin
receptors. For example, the RORα was found in both the thymus and spleen (Carrillo-Vico
et al., 2003). In addition, nuclear receptors have been found in lymphocytes (Jurkat cells),
human peripheral mononuclear cells (PBMCs), U937 cells, CD4 and CD8 cells (Garcia-
Maurino et al., 2000; Guerrero et al., 2000).
4.3. Melatonin receptors, immune system, and seasonal differences
In 1973, Vriend and Lauber measured the weight of spleens from deer mice after exposure
to different light intensities. They found that spleen weights averaged 1.5 mg after exposure
to 3.6 × 1011 photons, compared to 2.0 mg when exposed to photons at 5.6 × 1011 photons
(Vriend and Lauber, 1973). They suspected that endogenously produced melatonin might
have influenced the outcome of the study, although the melatonin levels were not actually
measured. There is a reported direct correlation between melatonin levels at its peak during
darkness, and the maximal immune cell proliferation (Carrillo-Vico et al., 2005). This was
confirmed when mice treated with the MT1 and MT2 antagonist luzindole at different times
of the light cycle; they observed that despite the time the luzindole was given, it blocked
splenocyte proliferation (Drazen et al., 2001).
Nelson and Demas noted that melatonin and glucocorticoids mutually oppose one another,
depending on the concentration (Nelson and Demas, 1997). Unlike melatonin,
glucocorticoids have been found to inhibit splenocyte proliferation (Nelson and Demas,
1997). Since melatonin levels peak during the night and glucocorticoid levels peak during
the day, they postulated that the reason for the variation in splenocyte proliferation through
the day was due to this melatonin–glucocorticoid opposition. They also reported that during
longer days, mice had reduced immunoglobulin G (IgG) expression and lower levels of
melatonin release (Demas and Nelson, 1996). Another study by Mahmoud and colleagues
observed that rats that were exposed to constant dark for 4 weeks showed a 3-fold increase
in their thymus weight (Mahmoud et al., 1994).
5. Melatonin receptors in the endocrine system
Melatonin appears to play key roles in the regulation of the endocrine system. These roles
include regulation of GnRH (gonadotrophin releasing hormone) release, stimulation of
oxytocin secretion, promotion of progesterone synthesis release, regulation of cortisol
production, and promotion of androgen production (Balik et al., 2004; Schaeffer and
Sirotkin, 1995; Tamura et al., 2009, 2008). Species differences exist in melatonin receptor
expression and action on the endocrine system.
5.1. Melatonin receptor localization
Melatonin receptors have been found in various tissues throughout the endocrine system.
MT1 and MT2 receptors have been found to be expressed in the pituitary gland, although
MT2 are less prevalent (Balik et al., 2004). Immunoblot analysis of murine line GnRH
secreting neurons was used to demonstrate expression of MT1 and MT2 receptors, as well as
the nuclear receptors RORα and RZRβ (Roy et al., 2001). Soras et al. in 2003 MT1 and
MT2 are present in the rat ovaries as demonstrated by RT-PCR and 2-[125I]iodomelatonin
binding (Soares et al., 2003). Niles and co-workers in 1999 used RT-PCR to detect MT1 and
MT2 receptor expression in human granulosa cells (Niles et al., 1999), the findings
confirmed by others Woo et al. (2001). MT1 receptor expression has been detected in the
adrenal glands of capuchin monkeys (Torres-Farfan et al., 2003). This was confirmed in rat
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adrenal gland tissue, however, MT2 receptors were not expressed (Richter et al., 2008).
Furthermore, MT1 receptors are expressed in sperm cells (Casao et al., 2010).
5.2. GnRH and other sex hormones regulation
Melatonin has been found to decrease GnRH, LH and FSH levels (Lang et al., 1983).
Vanecek and Vollrath found that melatonin’s inhibition of cAMP and cGMP production
causes the inhibition of GnRH release (Vanecek and Vollrath, 1990). They also found that
melatonin’s inhibitory effect is especially pronounced in rats younger than 14 days of age
(Vanecek and Vollrath, 1990). There have been other mechanisms proposed that explain
melatonin’s inhibitory effect on GnRH. Roy and colleagues used Northern blot to find that
melatonin can also affect GnRH expression at the transcriptional level (Roy et al., 2001).
This group also found that the melatonin receptor inhibitor, luzindole, attenuates melatonin’s
inhibitory effect on GnRH release (Roy et al., 2001). Another group, led by Woo and co-
workers has found that melatonin’s action on GnRH works via regulating mitogenic
responses via MAPK signaling (Woo et al., 2001). Roy and colleagues gave further
evidence of this phenomenon by showing that kinase inhibitors prevent melatonin from
blocking GnRH release (Roy and Belsham, 2002). Balik and colleagues also wrote that
melatonin blocks GnRH release by preventing oscillatory calcium release (Balik et al.,
2004). However, these investigators also mention that melatonin does not by itself prevent
calcium release, rather it depends on the melatonin receptor for this action (Balik et al.,
2004).
The discovery that melatonin promotes progesterone release was made by Webley and Luck
over 25 years ago (Webley and Luck, 1986). They found that melatonin exerts this effect at
high concentrations (200 pg/ml) and for a fairly long duration (8 h). Woo and co-workers
have found that melatonin has no effect on progesterone secretion from human granulosa-
luteal cells (Woo et al., 2001). On the contrary other authors claimed that melatonin
stimultes progesterone production when cells are given hGC and that LH receptors were
upregulated and GnRH receptors upregulated in ovaries.
5.3. Regulation of cortisol production
Although it has been more than 20 years since it has been shown, that melatonin can inhibit
serum cortisol levels (Aoyama et al., 1986), only recently the mechanism in which
melatonin directly regulates cortisol production was uncovered. MT1 receptors have been
found to directly inhibit cortisol production in the adrenal glands of capuchin monkey
(Torres-Farfan et al., 2003). These investigators used luzindole to antagonize melatonin
receptors, as well as RT-PCR to show that only MT1 receptors are expressed in the adrenal
gland. They later reported that melatonin also prevents the adrenal gland from responding to
ACTH (Richter et al., 2008). This group indicated that the MT1 receptors seem to also act
on the 3β-HSD enzyme, which is needed for cortisol production (Torres-Farfan et al., 2004).
5.4. Melatonin and diabetes
Scientists have been investigating the role of the pineal gland in glucose metabolism for
more than 70 years (Peschke, 2008). Rats with the pineal gland removed have been found to
have an increase in their glucose levels (Gorray and Quay, 1978). Pinealectomy also reduces
the adipose tissue’s response to insulin (Lima et al., 1998). Boden and colleagues noticed
that insulin secretion increases during the day, while melatonin secretion decreases (Boden
et al., 1996). Melatonin secretion has been found to decrease with age, and giving it to these
older rats has been found to restore insulin, leptin, and visceral fat levels to the level of
younger rats (Rasmussen et al., 1999). In 2009, there were three single nucleotide
polymorphisms (SNPs) identified near the MT1 receptor gene (specifically, rs2166706,
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rs1387153, and rs10830963) that are correlated with a higher instance of type 2 diabetes
(Chambers et al., 2009).
5.5. Localization of the melatonin receptors in the endocrine pancreas
Both MT1 and the MT2 receptors have been found to be present in the pancreas (Peschke,
2008). In 2002, Peschke found that MT1 receptors are present in the pancreatic islets, while
MT2 receptors are also present but in smaller quantities (Peschke, 2008). Muhlbauer and
Peschke also discovered that both MT1 and MT2 receptors are present in the islets of
Langerhans (Muhlbauer and Peschke, 2007). Ramracheya and co-workers confirmed the
presence of MT1 and MT2 receptors in the islet of Langerhans, and further described that
MT1 receptors are present in α cells, but not in β cells (Ramracheya et al., 2008). Peschke
also reported that the melatonin nuclear receptors RORα, RZRB, and RORγ can be detected
in the pancreatic tissues (Peschke, 2008).
The melatonin receptors are coupled to a Gi protein that inhibits adenylyl cyclase and cAMP
to mediate its signal transduction (Peschke, 2008). This was demonstrated when luzindole
was added to the pancreatic islets, resulting in the inhibition of melatonin’s signaling.
Peschke and colleagues in 2000 found that the G protein-coupled receptor can also act
through the phospholipase C/IP3 pathway (Peschke et al., 2000). Picinato and colleagues has
shown that melatonin reduces cAMP production in the pancreas and INS-1 cells (Picinato et
al., 2008). They also found that melatonin induces production of insulin growth factor (IGF)
and promotes insulin receptor tyrosine phosphorylation (Picinato et al., 2008). This in turn
activates PI3K/AKT and MEK/ERK pathways (Picinato et al., 2008). In addition, an
increase in calcium levels by melatonin can stimulate glucagon production (Ramracheya et
al., 2008).
6. Melatonin receptors in the reproductive and gestational tissues
6.1. Uterus
6.1.1. Myometrium—An important feature of the uterus is the well-defined 24-h rhythm
of contractility and electrical and endocrine activities in rodents, primates, and humans
(Lindström et al., 1984; Seron-Ferre et al., 1993). A classic example of such circadian
activity is the 24-h rhythm of spontaneous birth in humans (Myers and Nathanielsz, 1993;
Nathanielsz, 1994; Olcese, 2012; Panduro-Baron et al., 1994), with maximal birth rate
values during the night, at a time coinciding with maximal pineal melatonin secretion
(Arendt, 1996). The fact that the light–dark cycle can regulate the daily timing of birth and
uterine contractility has been shown for baboons, rhesus macaques (Ducsay and Yellon,
1991; Figueroa et al., 1990) and rats (Pang et al., 1985). Moreover, the increase of the blood
flow to the placenta during the night seems to play an important role in the parturition
(Harbert et al., 1979).
Melatonin plays an important role in the uterine contractility in rodents; however, the
expression of circadian activity differs from the pattern in humans with the peak of activity
at night compared to the day time. There were no effect of melatonin, for example on the
uterine contractility in sheep (Sadowsky et al., 1991). To the best of knowledge the uterine
melatonin receptors in sheep have not been described yet. MT1 receptor has been described
in the rat myometrium (Zhao et al., 2002) where it decreased uterine contractility
(spontaneous and oxytocin-induced) (Ayar et al., 2001).
Many studies showed a clear 24 h circadian patterns in myometrial activity in the pregnant
non-human primate (Figueroa et al., 1990; Honnebier et al., 1991; Honnebier and
Nathanielsz, 1994). Contractures switch to contractions at night time and the activity
reverses back to contractures the following day. This switch occurs for several nights before
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delivery finally occurs (Morgan et al., 1992). In the human uterus the functional MT1 and
MT2 receptors have been detected (Schlabritz-Loutsevitch et al., 2003). The expression of
these receptors differs in pregnant and non-pregnant uterus.
6.1.2. Endometrium—2-[125I]iodomelatonin binding and MT1 transcript was described
in rat endometrium during estrous cycle (Zhao et al., 2002). The expression of these
receptors is up-regulated by the melatonin treatment and is associated with the down-
regulation of the ER-beta and PRB (Chuffa et al., 2011). Influence of the melatonin on the
incidence of endometrial cancer has been suggested (Sandyk et al., 1992) and the presence
of the functional MT2 receptor was detected in the estrogen positive cell line derived from
patient with endometrial carcinoma (Kobayashi et al., 2003).
6.1.3. Placenta—Human amniotic epithelial cells expressed MT1, but not MT2 receptors
(Kaneko et al., 2011). MT1 and MT2 mRNA expression was demonstrated in the first
trimester placenta (Iwasaki et al., 2005). In the placenta at term immunohistochemistry
showed the presence of melatonin receptors (MT1, MT2, and RORα in both villous
cytotrophoblast and syncytiotrophoblast (STB) as well as in endothelial cells of fetal
capillaries and in the villous mesenchymal core (Lanoix et al., 2008). All three receptors
were detected using RT-PCR, Western blotting and confocal microscopy in the human term
placental tissues and in choriocarcinoma cell lines JEG-3 and BeWo (Lanoix et al., 2006).
Interestingly, the MT2 receptors have been found on the nuclear surface in addition to the
usual location on the membrane surface. It was reported that human term villous trophoblast
expresses melatonin synthesizing enzymes and produces 255 times more melatonin than the
pineal gland (Lanoix et al., 2008). Anti-apoptotic action of melatonin on the trophoblast
through the MT1 and MT2 dependent pathways was also demonstrated (Lanoix et al., 2012).
Furthermore, mRNA transcripts of the melatonin-synthesizing enzymes and both MT1 and
MT2 melatonin receptors were demonstrated in the first-tri- mester human placenta (Iwasaki
et al., 2005). MT1 was also detected in the rat placenta, and melatonin agonist decreased the
expression of placenta lactogen-II (PL-II) mRNA in cultured late-pregnancy rat placental
tissues (Lee et al., 1999, 2003).
Most recently an in-depth review on differential effects of melatonin on the human
trophoblast has been published (Lanoix et al., 2012).
6.2. Mammary gland
6.2.1. Mammary gland development—The binding sites for the 2-[125I]-melatonin
were found in the membrane and nuclei of mice mammary glands (Coto-Montes et al., 2003;
Recio et al., 1994). The binding depends on the developmental (puberty, pregnancy),
hormonal (estrus) and diurnal rhythm. The expression of MT1 receptor gene in the breast
tissues is decreased in the rat model of aging (Hill et al., 2010). This decline has been
associated with the increased incidence of ovarian cancer.
6.2.2. Breast cancer—Risk of the development of the breast cancer increased in the areas
located north to the equator (Borisenkov and Anisimov, 2011). The role of the light
pollution and the attendant effect on pineal gland in the breast cancer development has been
suggested decades ago (Anisimov, 2003; Anisimov et al., 2005; Cohen et al., 1978; Cos et
al., 2006; Cos and Sánchez-Barceló, 2000; Danforth et al., 1983). Melatonin administration
has been shown to decrease, but in some cases to increase or having no effect on the
development of the mammary gland tumors in mice and rats (Anisimov, 2003). In the breast
tissue melatonin receptors modulate estrogen receptor binding (Danforth et al., 1983). MT1
receptor is expressed in MCF-7 and MDA-MB-231 (human breast cancer cell lines) and in
the breast cancer tissues (Ram et al., 2002; Rogelsperger et al., 2011; Treeck et al., 2006). In
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MCF-7 cells melatonin reversibly inhibited cell proliferation and cell invasion (Mao et al.,
2010). As confirmed by immunohistochemistry and immunofluorescent/confocal
microscopy, MT1 receptor signal is localized in calveoli (Lai et al., 2008, 2009). There is a
crosstalk between MT1 receptor and estrogen receptors pathways in the breast cancer (Cos
et al., 2006). The MT1 expression is down regulated by exogenous estradiol and melatonin
in MCF-7 cells. Moreover the MT1 receptors expression is up regulated in the estrogens
receptors negative cells (MDA-MB-231) and down regulated in the estrogens receptors
positive cells (MCF-7) (Girgert et al., 2009). Recently identified microRNA such as Piwi
associated RNA is regulating MT1 gene expression as well (Esposito et al., 2011).
6.3. Ovarian tissue
To the best of our knowledge the melatonin in ovaries has been described extensively only
in human, but not in non-human primates. Melatonin plays as important role in the
regulation of the ovarian function and it has been detected in the human follicular fluid (FF)
(Brzezinski et al., 1987; Ronnberg et al., 1990). The FF melatonin had functional effect on
the progesterone production of human granulosa cells (GCs) (Brzezinski et al., 1992;
Webley and Luck, 1986; Webley et al., 1988). The [3H]melatonin binding sites in
cytoplasmic fractions of human ovaries were described by Cohen et al. decade earlier, in
1978 (Cohen et al., 1978). Subsequently melatonin-binding sites were detected in GCs using
2-[125I]iodomelatonin (Yie et al., 1995), MT1 and MT2 gene expression was documented in
human GCs with the prevalence of MT1 receptor (Niles et al., 1999). In human GCs
melatonin increased LH receptor mRNA levels via the mitogen-activated protein kinase
pathway and activation of Elk-1 (Woo et al., 2001) and stimulates oxytocin and insulin-like
growth factor-I release (Schaeffer and Sirotkin, 1995, 1997). Moreover, treatment with
melatonin protects luteinizing GCs from ROS (Taketani et al., 2011) and improves oocyte
quality in IVF cycles (Tamura et al., 2009). This finding indicates that melatonin might
activate both: different receptors and signal molecules. Interestingly, the proteomic data
from human cumulus cells and mural GCs from the antral follicle did not include melatonin
receptor (Huang and Wells, 2010). The importance of melatonin receptors is also suggested
by an association of the single nucleotide polymorphism (SNP) with the pathology of the
ovarian function. In the population of Chinese women SNP in the MT2 gene, rs10830963, is
the predisposing factor to the poly-cystic ovarian syndrome (Li et al., 2011).
MT1 receptors have been described in the human SK-OV-3 and OVCAR-3 ovarian
carcinoma cell lines, where their expression was up-regulated by melatonin treatment
(Treeck et al., 2006).
7. Melatonin receptors in the skin
In 1958 Lerner discovered that melatonin can cause lightening of the skin of frogs (Lerner et
al., 1959). We now appreciate many functions of melatonin in the skin, including
scavenging of free radicals, protection of fibroblasts and keratinocytes from UV radiation,
promotion of the anagen phase of the hair follicle, stimulation or inhibition of keratinocyte
proliferation (depending on concentration), blockade of apoptosis, and prevention of
carcinogenesis (Fischer et al., 2008a; Kobayashi et al., 2005; Slominski et al., 2008,
2005b,c). Melatonin also regulates melanin pigmentation (Slominski et al., 2005a, 2004b)
and has a potential utility in melanoma treatment (Fischer et al., 2006; Slominski et al.,
2005c). Several studies have given additional evidence of the importance of melatonin in the
skin. Esrefoglu et al. pinealectomized rats and then tracked them for 6 months (Esrefoglu et
al., 2005). Half of the rats were then given melatonin (4 mg/kg) during the last month of the
study. Pinealectomized rats showed reduced skin thickness and atrophy of the epidermis,
dermis, and the hair follicles (Esrefoglu et al., 2005). By comparison, the rats that were
given melatonin showed reduced skin abnormalities. Furthermore, “MT3” receptor knockout
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mice exposed to carcinogens (benzopyrene and dimethyl-benzanthracene) displayed a higher
incidence of developing skin cancer than wild type mice (Iskander et al., 2004).
7.1. Localization of melatonin receptor expression in the skin
MT1 and MT2 receptors have been found in the skin, as have the nuclear receptors RORα1,
RORα2, and RZR, and “MT3” (Fischer et al., 2008a; Slominski et al., 2008). These findings
confirm prior detection of melatonin binding sites in the epidermis and hair follicles of
mouse skin (Slominski et al., 1994) and in cultured melanoma cells (Slominski and Pruski,
1993). Expression of MT1 and MT2 measured by RT-PCR made it clear that receptor
expression depends on the species and cellular compartments (Slominski et al., 2005c) as
well as on environmental regulation, which induced alternative splicing (Slominski et al.,
2005a). MT1 receptor expression has been detected by immunocytochemistry in skin
stratum granulosum, stratum spinosum, upper and inner root sheath, eccrine sweat gland,
and blood vessel endothelium. MT2 receptor expression has been detected in the inner root
sheath, eccrine sweat gland, and blood vessel endothelium (Slominski et al., 2005c). MT2
receptors are not as highly expressed in the epidermal cells of human skin, but are expressed
in the epidermis of C57BL/6 mice (Slominski et al., 2005c). Kobayashi and colleagues has
found MT2 and RORα receptor expression in hair follicles (Kobayashi et al., 2005). “MT3”
receptor expression has been detected in keratinocytes, melanocytes, and fibroblasts
(Slominski et al., 2005a). The nuclear receptors RORα/RZR have been found in adult and
neonatal normal and immortalized epidermal keratinocytes, normal epidermal melanocytes,
dermal fibroblasts and melanomas (Slominski et al., 2005a,c). For most comprehensive
reviews on melatonin and the skin we refer to (Fischer et al., 2008b; Slominski et al., 2005a,
2008a, 2005c).
7.2. Hair growth
An early study claimed that melatonin had an inhibitory effect on hair regrowth (Houssay et
al., 1966). Recent evidence however suggests otherwise (Fischer et al., 2004; Ibraheem et
al., 1994). Adding melatonin at various concentrations (50–300 ng/L) to hair follicles
collected from goats promoted hair growth (Ibraheem et al., 1994). The fur growth in
rodents may be mediated by melatonin binding sites/receptors expressed in hair follicles,
since these were identified in the murine skin showing hair cycle dependent pattern of
expression (Kobayashi et al., 2005; Slominski et al., 1994). Also melatonin has been found
to promote the anagen phase of murine hair cycle and these actions seem to be mediated by
the MT2 receptor, as this is the predominate receptor in the cells of question (Kobayashi et
al., 2005; Slominski et al., 2004a). These findings prompted a randomized, double-blind
study of hair growth in women suffering from androgenic alopecia. Subjects were given
melatonin (0.1%) topically each evening for 6 months. Melatonin caused increased hair
growth in patients with androgenetic alopecia, but not in patients suffering from diffuse
alopecia (Fischer et al., 2004). These effects were interpreted as induction of hair growth by
prolongation of the anagen phase, in part via retardation of the transition to catagen and/or
by promotion of the transition from telogen to anagen (Fischer et al., 2008a). These clinical
studies provided evidence for a positive effect of melatonin in human hair growth, indicating
that melatonin receptors are realistic target for hair growth regulation in humans (Fischer et
al., 2008a). For more detailed review on melatonin and hair growth we refer to (Fischer et
al., 2008a), while on melatonin and hair or skin pigmentation to (Slominski et al., 2004b,
2005b).
7.3. Vitiligo
There are two main theories about the causes of vitiligo, a skin condition where pigment is
lost in patches of otherwise normal skin. One theory is that vitiligo is caused by the immune
system attacking the melanocytes, while others feel that the abnormal function of a
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metabolic pathway affects the melanocyte (Dell’anna and Picardo, 2006). Lerner proposed
in 1960 that excessive melatonin in the peripheral nerve lightens the skin, and that it can also
decrease melanin formation (Lerner, 1960). This prompted a proposal that melatonin may
have play a role in vitiligo. Specifically it was postulated that a deregulation of
melanogenesis, which involves activation of melatonin receptor, causes the destruction of
melanocytes due to accumulation of toxic intermediates of melanogenic pathway, and as
consequence vitiligo (Slominski et al., 1989). The proposed mechanism is that the
overactive melatonin receptor blocks the melanin synthesis pathway, causing a buildup of
toxic intermediate products and autodestruction of melanocytes (Slominski et al., 1989).
Since the central role of melatonin receptors in vitiligo was questioned by some authors
(Schallreuter et al., 2008), the same authors explained further that the interference with
melanogenesis could be due to a mutated or malfunctioning melatonin receptor rather than
activation of normal receptor (Slominski et al., 2008). Furthermore, the excess of melatonin
could in fact protect cells because of free radical scavenging activities of melatonin and its
metabolites (Slominski et al., 2008). The definitive role of melatonin in vitiligo is obviously
still subject to debate.
8. Melatonin receptors in the gastrointestinal tract
The first major report of melatonin activity in the GI tract was by Quastel and Rahamimoff,
who reported that melatonin decreased spontaneous contraction of the intestine (Quastel and
Rahamimoff, 1965). Immunohistochemistry was used to identify melatonin localization in
the mucous membrane in the intestine (Bubenik et al., 1977). Melatonin was also detected in
the colon of rats by using immunofluorescence microscopy (Holloway et al., 1980). Not
only is melatonin found in the GI tract, but evidence favors the idea that it can be produced
locally by the intestine. Both of the rate limiting enzymes for melatonin production,
AANAT and HIOMT, are expressed in the intestinal wall (Konturek et al., 2007a). Further,
melatonin levels can be from 10 to 100 times greater in the intestine than in serum (Bubenik,
2008).
Melatonin plays various important roles in the GI tract. One role is to act as a physiological
antagonist to serotonin (Bubenik, 2008). Although the mechanism is unknown, there are two
theories for this action: melatonin blocks serotonin by acting through the CCK2 and 5HT3
receptors (Thor et al., 2007), or melatonin acts through the MT2 receptor to oppose
serotonin’s action (Bubenik, 2008). Melatonin secretion is also found to increase in the
intestine during fasting (Bubenik, 2008). The role of this increase in melatonin secretion
could be to decrease peristalsis, thus giving the body more time to absorb nutrients in food.
Melatonin can also stimulate the secretion of mucosal bicarbonate through increasing the
calcium release in the enterochromaffin cell (Sjoblom et al., 2003). This action seems to be
mediated by the MT2 receptor, as both luzindole and the MT2 receptor antagonist N-
pentanoyl-2-benzyltryptamine (DH 97) inhibit melatonin’s actions (Sjoblom et al., 2003).
Melatonin has also been found to increase pancreatic secretion of amylase and
cholecystokinin via activation of MT2 receptors (Jaworek et al., 2007). An important
receptor-independent action of melatonin in the GI tract is its action as a free radical
scavenger (Konturek et al., 2006). Importantly, preventive role of melatonin against ulcer
formation or its healing is well established (Brzozowska et al., 2009; Celinski et al., 2011;
Ganguly et al., 2010; Konturek et al., 2008, 2006).
8.1. Localization of melatonin receptors in the GI tract
Melatonin receptors have been found throughout the GI tract, with the fewest amount of the
receptors in the mouth and intestine, and the highest amount in the colon and jejunum
(Konturek et al., 2007a). Although both MT1 and MT2 receptors are expressed throughout
the GI tract, it seems that the MT2 receptor predominates (Konturek et al., 2007b). The MT2
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receptors have also been detected in enterochromaffin cells in the intestine (Sjoblom et al.,
2003). Although co called “MT3” receptor has not been found in humans to date, they have
been detected in the intestine of hamsters. Paul et al. used two drugs to show the presence of
“MT3” receptors: prazosin, which block both α1 adrenergic and “MT3” receptors, and MC-
NAT, a putative ligand for “MT3” receptors (Paul et al., 1999).
9. Melatonin receptors in bone
The membrane melatonin receptors have been detected in both osteoblasts and osteoclasts
using the ligand 2-bromomelatonin (Suzuki et al., 2008). MT1 receptors have also been
found in osteosarcoma cells and even in bone marrow stroma cells (Toma et al., 2007). MT1
receptors have also been detected in secretory ameloblasts, the cells of the stratum
intermedium and stellate reticulum, external dental epithelial cells, odontoblasts, and dental
sac cells (Kumasaka et al., 2010). Melatonin has therapeutic activity in bones, as it promotes
osteoblastic differentiation and bone strengthening (Roth et al., 1999). Cardinali et al.
reported that melatonin not only increases osteoblastic activity, but also inhibits osteoclasts
and even promotes the osteoblastic protein osteoprotegrin (Cardinali et al., 2003; Koyama et
al., 2002). Thus, melatonin could potentially be used as a therapy for osteoporosis.
10. Melatonin receptors in kidneys
Melatonin receptors are expressed in the duck kidney, as detected by Song et al. nearly 20
years ago (Song et al., 1992). Melatonin receptors are expressed predominately in the kidney
membrane area and basolateral membranes (Song et al., 1997). Drew et al. also reported that
MT1 and MT2 receptors are expressed in the human fetal kidney cortex (Drew et al., 1998).
Melatonin has several applications related to the renal system. Quiroz et al. described that
melatonin can protect the kidneys from inflammation that can cause renal damage (Quiroz et
al., 2008). Melatonin can protect the kidneys from oxidative damage done by mercuric
chloride and can even regulate glomular filtration (Drew et al., 1998; Nava et al., 2000).
11. Conclusions
Although melatonin was identified for more than 50 years ago, only more recently have
scientists begun to discover its numerous actions in peripheral tissues. Table 1 summarizes
the expression of the different melatonin receptors in peripheral tissues and the primary
physiological effects in each. The many roles of melatonin include regulation of circadian
rhythms, acting as a neurotransmitter or a hormone to regulate numerous organ systems, and
as an antioxidant (Reiter et al., 2000; Tan et al., 1993). Some of these actions are mediated
through its G protein coupled membrane receptors: MT1 and MT2, while others are believed
to be receptor independent (Dubocovich and Markowska, 2005; Reiter et al., 2007).
Although “MT3” receptors have not yet been found in humans, they have been found to be
expressed in the various tissues of both hamsters and rabbits (Nosjean et al., 2000; Pintor et
al., 2001).
Melatonin can also act on the retionic acid family of nuclear receptors to mediate many of
its actions (Smirnov, 2001). How exactly melatonin interacts with the nuclear receptors
remains a controvertial topic. Carlberg and Wiesenberg found that melatonin can directly
interact with the nuclear receptors (Carlberg et al., 1994), whereas Ram and collegueas
believe that melatonin mediates its actions on the nuclear receptors through MT1 receptor
activation (Ram et al., 2002). More investigation is needed to determine how melatonin
regulates these nuclear receptors, since based on the crystal structure of ROR cholesterol
sulfate but not melatonin was defined as its natural ligand (Kallen et al., 2004).
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Also under active investigation is whether a mutated melatonin receptor causes vitiligo. As
technology progresses, molecular and genetic tools are being utilized to discover melatonin
receptor expression and their physiological roles in physiology and disease. These receptors
make attractive pharmacological targets for immunomodulation, regulation of endocrine
functions, anti-cancer activity, circadian activity, cardiovascular activity, skin pigmentation,
hair growth and aging. Thus, expanding our knowledge of the expression, regulation,
signaling and function of melatonin receptors in peripheral cells and tissues may have an
impact on the pharmacotherapy of a wide array of diseases.
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• Melatonin is produced in mammals, plants, unicellular eukaryotes, and bacteria.
• It acts as neurotransmitter, hormone, cytokine, metabolic modulator and
antioxidant.
• Melatonin regulates functions of peripheral organs.
• Melatonin activates membrane bound or nuclear receptors.
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The biosynthetic pathway of melatonin. Melatonin is synthesized from tryptophan in a
multistep process. The final two synthetic steps mediated by AANAT and HIOMT are
considered to be rate limiting. TRPH: tryptophan hydroxylase, AAD: aromatic amino acid
decarboxylase, AANAT: arylalkylamine N-acetyltransferase, HIOMT: hydroxyindole-O-
methyl transferase.
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Signaling schematic of melatonin receptor subtypes. Melatonin exerts many of its biological
actions through MT1 or MT2 membrane receptors (G protein-coupled) or, according to
some authors, via nuclear receptors (RORa/RZR1). Signaling pathways known to be
activated by melatonin receptors are shown. Quinone reductase II (“MT3” receptors) have
been demonstrated only in hamster and rabbit.
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Table 1
Tissue distribution of melatonin receptors.
Tissues Melatonin receptors expressed Role of melatonin
SCN MT2 Regulate circadian rhythm
Retina MT2, RORα Decrease dopamine release
Vasculature MT1, MT2 MT1: vasoconstrictor
MT2: vasodilator
Immune system MT1, MT2, RORα Inhibit leukotriene rolling
Promote immune cell proliferation
Stimulates IL2 and IL6 production
Reproducive system MT1, MT2 Decreases GnRH, LH, FSH release
Pancreas MT1, MT2, RORα Decrease insulin release
Skin MT1, MT2, RORα Regulate hair growth, and functions of epidermis
GI tract MT1, MT2 Decrease gastric contraction, peristalsis, and sertonin’s actions
Increases bicarbonate, amylase, and CCK release
Bone MT1, RORα Increases osteoblastic activity and decrease osteoclastic activity
Kidneys MT1, MT2 Protects from inflammation, regulate glomerular filtration
Placenta MT1, MT2, RORα ROS scavenger, decrease apoptosis
Uterus MT1, MT2 Myometrial contractility
Endometrium MT1, MT2 Trophoblast invasion in early pregnancy
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